Results 81 to 90 of about 461 (138)

Cardiovascular pharmacotherapy in 2025. [PDF]

Eur Heart J Cardiovasc Pharmacother
Tamargo J, Agewall S, Ambrosio G, Borghi C, Cerbai E, Dan GA, Drexel H, Ferdinandy P, Grove EL, Klingenberg R, Morais J, Parker W, Rocca B, Sulzgruber P, Semb AG, Sossalla S, Kaski JC, Dobrev D.   +17 more
europepmc   +1 more source

Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten. [PDF]

Clin Pharmacokinet
Xu D, Lutz JD, Divanji P, Li J, Benattia Y, Griffith A, Heitner SB, Kupfer S, German P.   +8 more
europepmc   +1 more source

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Saleh D, Kim EY, Hussain K, Samhan A, Shi M, Meng Z, Schormann E, Bindra P, Cheema B, Fullenkamp DE, Baldridge AS, Puthumana JJ, Rigolin VH, Cremer PC, Flaherty JD, Choudhury L.   +15 more
europepmc   +1 more source

Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology. [PDF]

Card Fail Rev
Li-Wen Chu E, Seung Kim D, Masri A.
europepmc   +1 more source

A New Era in the Management of Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Perez-Asensio A, Llamas-Gomez H, Lara-Palomo A, Villar-Ruiz A, Jimenez-Mendez C, Palomino-Doza J.   +5 more
europepmc   +1 more source

The Dawn of a New Era in Hypertrophic Cardiomyopathy. [PDF]

Acta Cardiol Sin
Yu WC.
europepmc   +1 more source

Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study

Journal of Cardiovascular Magnetic Resonance
Ahmad Masri, MD, Rhanderson Cardoso, MD, Theodore Abraham, MD, Lubna Choudhury, MD, Florian Rader, MD, Sara Saberi, MD, Albree Tower-Rader, MD, Andrew Wang, MD, Stephen Heitner, MD, Stuart Kupfer, MD, Fady Malik, MD, PhD, Chiara Melloni, MD, Jenny Wei, PhD, Amy Wohltman, Raymond Kwong, MD   +14 more
doaj   +1 more source

A plain language summary of the SEQUOIA-HCM study: aficamten for symptomatic obstructive hypertrophic cardiomyopathy. [PDF]

Future Cardiol
Maron MS, Olivotto I, van Sinttruije M.
europepmc   +1 more source

Cardiac myosin inhibitors in hypertrophic cardiomyopathy. [PDF]

J Cardiovasc Imaging
Lim J, Kim HK.
europepmc   +1 more source

Cardiac myosin inhibitors in hypertrophic cardiomyopathy: advancing care with caution. [PDF]

Ann Med Surg (Lond)
Rehman Z, Ahsaan F, Latif B, Anjum AF, Yokolo H.   +4 more
europepmc   +1 more source